Status:
COMPLETED
MEDITOXIN® in Treatment of Crow's Feet Line
Lead Sponsor:
Medy-Tox
Conditions:
Crow's Feet Lines
Eligibility:
All Genders
20-65 years
Phase:
PHASE3
Brief Summary
to determine the efficacy and safety of Meditoxin® in treatment of crow's feet line
Eligibility Criteria
Inclusion
- Male or female of at least 20 to 65 years old
- Bilaterally symmetrical moderate-to-severe CFL at maximum smile on the FWS as rated by the investigator
Exclusion
- Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis
- Patients with allergy or hypersensitivity to the investigational drugs or their components
- Patients who have bleeding tendency or taking anti-coagulant
- Female subjects who are pregnant or lactating. Female subjects of childbearing age who have a plan to get pregnant during the study period, or do not use available contraceptive methods (Women of childbearing age should have negative urine pregnancy test results at baseline visit (0 week) prior to the first injection.)
- Patients who are participating in other clinical trials or have participated in other clinical trials 30 days before screening
- Patients who are unable to communicate or follow the instructions
- Patients who are not eligible for this study based on the judgment of an investigator
Key Trial Info
Start Date :
August 17 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 14 2018
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT03317574
Start Date
August 17 2017
End Date
May 14 2018
Last Update
March 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Gyeonggi-do, South Korea